Who
Donald Olds
Director
Company insider
Files Form 4 as: Director, Retension Pharmaceuticals; Director, Grace Therapeutics.
In numbers
- Trades disclosed
- 7
- Buys
- 1
- Sells
- 0
- Bought
- $781
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 12 Nov 2021
- Last trade
- 13 Oct 2026
- Last filed
- 13 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Oct 2026filed 13 Oct 2026 | RTSN Retension PharmaceuticalsBiotechnology | SEC FORM 4 Code C | —5,637 | filing |
| 13 Oct 2026filed 13 Oct 2026 | RTSN Retension Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code C | —5,637 | filing |
| 8 Oct 2026filed 8 Oct 2026 | RTSN Retension Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,636 at $0.00 | filing |
| 31 Aug 2023filed 5 Sep 2023 | GRCE Grace TherapeuticsBiotechnology | SEC FORM 4 Bought | $781381 at $2.05 | filing |
| 14 Jul 2023filed 18 Jul 2023 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 28 Sep 2022filed 30 Sep 2022 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 12 Nov 2021filed 16 Nov 2021 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,100 at $0.00 | filing |
News
Grace Therapeutics (NASDAQ:GRCE) Upgraded at Wall Street ZenGRCE · themarketsdaily.com · 15 Oct 2026
0 headlines in the last 90 days name Donald Olds; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.